Evidence map›Paper›PMID 37786484›Full record

ArticlePalliative medicine reports2023

Clinical Features of Patients With Hematological Malignancies Treated at the Palliative Care Unit.

Hiromichi Yamane, Nobuaki Ochi, Ayaka Mimura, Yoko Kosaka, Naruhiko Ichiyama, Tatsuyuki Kawahara, Yasunari Nagasaki, Hidekazu Nakanishi, Nagio Takigawa

Open access · goldAbstract read
In one paragraph

Article in Palliative medicine reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Hiromichi YamaneDepartment of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan.
Nobuaki OchiDepartment of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan.
Ayaka MimuraDepartment of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan.
Yoko KosakaDepartment of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan.
Naruhiko IchiyamaDepartment of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan.
Tatsuyuki KawaharaDepartment of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan.
Yasunari NagasakiDepartment of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan.
Hidekazu NakanishiDepartment of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan.
Nagio TakigawaDepartment of General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan.
Kawasaki Medical School · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In Japan, the number of patients with aggressive hematological malignancies (PHMs) admitted at the palliative care unit (PCU) in their end-of-life (EOL) stage was fewer than that of patients with solid tumors due to several reasons. The assessment of patient characteristics and the methods of survival prediction among PHMs in the EOL stage are warranted. Objectives: This study aimed to identify the current medical status and the method of survival prediction among PHMs treated at the PCU. Setting/Subjects/Measurements: We retrospectively analyzed the clinical data of 25 PHMs treated at our PCU between January 2017 and December 2020. The association between survival time and the palliative prognostic score (PAP) and palliative prognostic index (PPI) was analyzed. Results: The average age of the PHMs was higher than that of patients with lung cancer as a control. The median survival time of the PHMs was shorter than the control group. Most PHMs could not receive standard chemotherapy, and the most common cause of death was disease-related organ failure. Significant associations were observed between the survival time and each PAP/PPI value in patients with malignant lymphoma, but not in those with leukemia. Conclusion: The PHMs in the PCU had a lower median survival time than the control group. These results were induced by the result of patient selection to avoid treatment-related severe toxicity. The survival prediction using the PAP and PPI was less accurate in patients with leukemia.

Indexed as

end-of-life carepalliative care unitpatients with hematological malignanciessurvival prediction

Identifiers

PMID37786484
PMCPMC10541919
OpenAlexW4387142661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.